The nitroimidazooxazines (PA-824 and analogs): Structure-activity relationship and mechanistic studies

Future Medicinal Chemistry

Volumn 2, Issue 8, 2010, Pages 1295-1304

  Denny, William A ^a   Palmer, Brian D ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BIPHENYL DERIVATIVE; NITRIC OXIDE; NITROIMIDAZOOXAZINE; NITROREDUCTASE; OXAZINE DERIVATIVE; REACTIVE NITROGEN SPECIES; UNCLASSIFIED DRUG;

BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; MICROARRAY ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; STEADY STATE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS;

EID: 77956040170     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.207     Document Type: Review

References (35)

1. Barry CE, Boshoff HIM, Dowd CS. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 10, 3239-3262 (2004).
2. Nagarajan K, Shankar RG, Rajappa S, Shenoy SJ, Costa-Pereira R. Nitroimidazoles XXI. 2,3-dihydro-6-nitroimidazo[2,1-b] oxazoles with anti-tubercular activity. Eur. J. Med. Chem. 24, 631-633 (1989).
3. Ashtekar DR, Costa-Perira R, Nagarajan K, Vishvanathan N, Bhatt AD, Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 37, 183-186 (1993).
4. Sasaki H, Haraguchi Y, Itotani M et al. Synthesis and anti-tuberculosis activity of a novel series of optically active 6-nitro-2,3- dihydroimidazo[2,1- b]oxazoles. J. Med. Chem. 49, 7854-7860 (2006).
5. Stover CK, Warrener P, Van Devanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-966 (2000).
6. Hu Y, Coates ARM, Mitchison DA. Comparison of the sterilizing activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 12, 69-73 (2007).
7. Manjuanatha UH, Lahiri R, Randhawa B, Dowd CS, Krahenbuhl JL, Barry CE. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob. Agents Chemother. 50, 3350-3354 (2006).
8. Bashiri G, Squire CJ, Moreland NJ, Baker EN. Crystal structures of F420- dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. J. Biol. Chem. 283, 17531-17541 (2008).
9. Bashiri G, Squire CJ, Baker EN, Moreland NJ. Expression, purification and crystallization of native and selenomethionine labeled Mycobacterium tuberculosis FGD1 (Rv0407) using a Mycobacterium smegmatis expression system. Protein Expr. Purif. 54, 38-44. 2007.
10. Manjunatha UH, Boshoff H, Dowd CS et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 431-436 (2006).
11. Bollo S, Nunez-Vergara LJ, Squella JA. Cyclic voltammetric determination of free radical species from nitroimidazopyran: a new antutuberculosis agent. J. Electroanalytical Chem. 562, 9-14 (2004).
12. Yanez C, Bollo S, Nunez-Vergara LJ, Squella JA. Voltammetric determination of nitroimidazopyran drug candidate for the treatment of tuberculosis. Anal. Lett. 34, 2335-2348(2001).
13. Anderson RF, Shinde SS, Maroz A, Boyd M, Palmer BD, Denny WA. Intermediates in the reduction of the anti-tuberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine, in aqueous solution. Org. Biomol. Chem. 6, 1973-1980 (2008).
14. Singh R, Manjunatha U, Boshoff HIM et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322, 1392-1395 (2008).
15. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, 2131-2134 (2006).
16. Manjuanatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun. Integr. Biol. 2, 215-218(2009).
17. Maroz A, Shinde SS, Franzblau SG et al. Release of nitrite from the anti-tubercular nitroimidazole drug PA-824 and analogs upon one-electron reduction in protic, non-aqueous solvent. Org. Biol. Chem. 6, 1973-1980 (2008).
18. Thompson AM, Blaser A, Anderson RF et al. Synthesis, reduction potentials and anti-tubercular activity of ring A/B analogs of the bioreductive drug (6S)-2-nitro-6-{[4- (trifluoromethoxy)benzyl]oxy}-6,7-dihydro- 5H-imidazo[2,1-b][1,3]oxazine (PA-824). J. Med. Chem. 52, 637-645 (2009).
19. Orita A, Miwa K, Uehara G, Otera J. Integration of solventless reaction in a multistep process: application to an efficient synthesis of PA-824. Adv. Synth. Catal. 349, 2136-2144 (2007).
20. Wardman P, Clarke DE. Oxygen inhibition of nitroreductase: electron transfer from nitro radical-anions to oxygen. Biochem. Biophys. Res. Commun. 69, 942-949 (1976).
21. Li X, Manjunatha UH, Goodwin MB et al. Synthesis and anti-tubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4- (trifluoromethoxy) benzyloxy)-6,7-dihydro- 5H-imidazo[2,1-b][1,3]oxazines, analogs of PA-824. Bioorg. Med. Chem. Lett. 18, 2256-2262 (2008).
22. Sutherland HS, Blaser B, Kmentova I et al. Synthesis and structure-activity relationships of anti-tubercular 2-nitroimidazooxazines bearing heterocyclic side chains. J. Med. Chem. 53, 855-866, 2010.
23. Nuermberger E, Rosenthal I, Tyagi S et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50, 2621-2625 (2006).
24. Fu LM, Tai SC. The differential gene expression pattern of Mycobacterium tuberculosis in response to capreomycin and PA-824 versus first-line TB drugs reveals stress- and PE/PPE-related drug targets. Int. J. Microbiol. DOI: 10.1155/2009/879621 (2009) (Epub ahead of print).
25. Koul A, Vranckx L, Dendouga N et al. Diarylquinolines are bactericidal for dormant Mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273-25280 (2008).
26. Debnath AK, Lopez de Compadre RL, Debnath G, Shusterman AJ, Hansch C. Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity. J. Med. Chem. 34, 786-797 (1991).
27. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Safety, tolerability and pharmacokinetics of PA-824 in healthy subjects. Antimicrob. Agents Chemother. 53, 3720-3725 (2009).
28. Kim P, Kang S, Boshoff HI et al. Structure-activity relationships of anti-tubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships. J. Med. Chem. 52, 1329-1344 (2009).
29. Kim P, Zhang L, Manjunatha UH et al. Structure-activity relationships of anti-tubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J. Med. Chem. 52, 1317-1328(2009).
30. Palmer BD, Thompson AM, Sutherland HS et al. Synthesis and structure-activity studies of biphenyl analogs of the nitroimidazooxazine tuberculosis drug PA-824. J. Med. Chem. 53, 282-294 (2010).
31. Falzari K, Zhu Z, Pan D, Liu H, Hongmanee P, Franzblau SG. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49, 1447-1454 (2005).
32. Ippolito JA, Kanyo ZF, Wang D et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 51, 3353-3356 (2008).
33. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Assessment of the effects of the nitroimidazo-oxazine, PA-824, on renal function in healthy subjects. Antimicrob. Agents Chemother. 53, 3726-3733 (2009).
34. Ginsberg AM, Diacon A, Dawson R et al. Extended early bactericidal activity (EBA) of PA-824, a novel drug for tuberculosis treatment. Presented at: 48th Annual ICAAC/ IDSA 46th Annual Meeting, Washington DC, USA. 25-28October 2008.
35. de Carvalho LPS, Lin G, Jiang X, Nathan C. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J. Med. Chem. 52, 5789-5792 (2009).